Literature DB >> 20122610

Predictors of mortality within three months in the patients with malignant pleural effusion.

Mehmet Oğuzhan Ozyurtkan1, Akin Eraslan Balci, Muharrem Cakmak.   

Abstract

BACKGROUND: Malignant pleural effusion (MPE) has a limited life expectancy (3-12 months). We investigated the predictors of the early mortality (EM) within three months.
METHODS: The patients were retrospectively grouped according to the death within three months (Group I) and survival more than three months (Group II). Demographical, clinical, and biochemical parameters in the fluid were analysed to determine their effects on the EM. The 30-day response rate of talc pleurodesis was investigated.
RESULTS: The study included 85 patients (Group I/Group II=40/45). The patients in Group I died within a median of 28 days. Twenty-six patients in Group II died in a median of 205, but 19 were still alive (median 200 days). The median survival was longer in renal cell, colorectal, breast, liver, ovarian and oropharynx carcinoma, and mesothelioma. Sixty-two patients (63%) underwent talc pleurodesis, which prevented the fluid reaccumulation (p=0.04). The significant factors of the EM in the univariate analysis were the presence of high-risk tumors (lung, stomach, soft tissue, bladder, esophagus, prostate, cervix, and lymphoma), the low Karnofsky performance score (KPS) (p<0.0001), the low pH value of the fluid (p=0.05), and the low concentration of glucose (p=0.01), total protein (p<0.0001), and albumin (p<0.0001) in the fluid. According to the multivariate analysis high-risk tumors (p=0.03), a lower KPS (p<0.001), and glucose value (p=0.04) were the predictors of the EM.
CONCLUSION: Talc pleurodesis prevents the fluid reaccumulation. High-risk tumors, a poor performance status, and lower pleural fluid glucose concentration are predictors of the EM within three months in the patients with a MPE. Copyright 2009 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20122610     DOI: 10.1016/j.ejim.2009.09.012

Source DB:  PubMed          Journal:  Eur J Intern Med        ISSN: 0953-6205            Impact factor:   4.487


  12 in total

1.  Mortality among patients with pleural effusion undergoing thoracentesis.

Authors:  Erin M DeBiasi; Margaret A Pisani; Terrence E Murphy; Katy Araujo; Anna Kookoolis; A Christine Argento; Jonathan Puchalski
Journal:  Eur Respir J       Date:  2015-04-02       Impact factor: 16.671

2.  Melanoma brain metastases: is it time to reassess the bias?

Authors:  Jaclyn C Flanigan; Lucia B Jilaveanu; Mark Faries; Mario Sznol; Stephan Ariyan; James B Yu; Jonathan P S Knisely; Veronica L Chiang; Harriet M Kluger
Journal:  Curr Probl Cancer       Date:  2011 Jul-Aug       Impact factor: 3.187

3.  Vascular endothelial growth factor and protein level in pleural effusion for differentiating malignant from benign pleural effusion.

Authors:  Da-Wei Wu; Wei-An Chang; Kuan-Ting Liu; Meng-Chi Yen; Po-Lin Kuo
Journal:  Oncol Lett       Date:  2017-07-20       Impact factor: 2.967

4.  Prognostic value of aberrant hypermethylation in pleural effusion of lung adenocarcinoma.

Authors:  Maribel Botana-Rial; Loretta De Chiara; Diana Valverde; Virginia Leiro-Fernández; Cristina Represas-Represas; Victor Del Campo-Pérez; Alberto Fernández-Villar
Journal:  Cancer Biol Ther       Date:  2012-09-06       Impact factor: 4.742

5.  Breast and Lung Effusion Survival Score Models: Improving Survival Prediction in Patients With Malignant Pleural Effusion and Metastasis.

Authors:  Sofia Molina; Gabriela Martinez-Zayas; Paula V Sainz; Cheuk H Leung; Liang Li; Horiana B Grosu; Roberto Adachi; David E Ost
Journal:  Chest       Date:  2021-05-11       Impact factor: 10.262

6.  Efficacy and safety of talc pleurodesis for malignant pleural effusion: a meta-analysis.

Authors:  Huan Xia; Xiao-Juan Wang; Qiong Zhou; Huan-Zhong Shi; Zhao-Hui Tong
Journal:  PLoS One       Date:  2014-01-27       Impact factor: 3.240

7.  Predicting survival in malignant pleural effusion: development and validation of the LENT prognostic score.

Authors:  Amelia O Clive; Brennan C Kahan; Clare E Hooper; Rahul Bhatnagar; Anna J Morley; Natalie Zahan-Evans; Oliver J Bintcliffe; Rogier C Boshuizen; Edward T H Fysh; Claire L Tobin; Andrew R L Medford; John E Harvey; Michel M van den Heuvel; Y C Gary Lee; Nick A Maskell
Journal:  Thorax       Date:  2014-08-06       Impact factor: 9.139

8.  Predictors of survival in patients who underwent video-assisted thoracic surgery talc pleurodesis for malignant pleural effusion.

Authors:  Dong Woog Yoon; Jong Ho Cho; Yong Soo Choi; Jhingook Kim; Hong Kwan Kim; Jae Ill Zo; Young Mog Shim
Journal:  Thorac Cancer       Date:  2016-05-05       Impact factor: 3.500

9.  Impact of Her-2 Overexpression on Survival of Patients with Metastatic Breast Cancer

Authors:  Giovana Tavares dos Santos; Maiquidieli Dal Berto; João Carlos Prolla; Ivana Beatrice Mânica da Cruz; Adriana Vial Roehe; Rosicler Luzia Brackmann; Keli Critine Reiter; Claudia Giuliano Bica
Journal:  Asian Pac J Cancer Prev       Date:  2017-10-26

10.  Indwelling pleural catheters for malignancy-associated pleural effusion: report on a single centre's ten years of experience.

Authors:  Nikolaj Frost; Martin Brünger; Christoph Ruwwe-Glösenkamp; Matthias Raspe; Antje Tessmer; Bettina Temmesfeld-Wollbrück; Dirk Schürmann; Norbert Suttorp; Martin Witzenrath
Journal:  BMC Pulm Med       Date:  2019-12-02       Impact factor: 3.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.